•
LY
LYEL
Lyell Immunopharma, Inc. Common Stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
507.73M
Volume
193.50K
52W High
$45.00
52W Low
$7.65
Open
$23.93
Prev Close
$23.90
Day Range
23.51 - 25.00
About Lyell Immunopharma, Inc. Common Stock
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Latest News
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
GlobeNewswire Inc.•Dec 9
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
GlobeNewswire Inc.•Dec 7
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
GlobeNewswire Inc.•Nov 3
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Benzinga•Jul 29
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
GlobeNewswire Inc.•Jun 23
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
GlobeNewswire Inc.•May 1
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Benzinga•Oct 24
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.•Oct 4